Table 2.
Safety and efficacy of high-intensity focused ultrasound (HIFU) for locally advanced pancreatic cancer (LAPC).
| Reference | # pts | Age, yrs | RECIST | Median OS | Morbidity | Pain Relief |
|---|---|---|---|---|---|---|
| Gao [31] | 39 | med 58 (42–79) | CR 0 PR 5 (12.8%) SD 25 (64.1%) PD 9 (23.1%) |
11.0 months | 12.8% | Total 31 (79.5%) Complete 9 (23.1%) Partial 22 (56.4%) † |
| Li [32] | 16 | mean 62 (49–72) | CR 0% * PR 43.7% SD 25% PD 31.3% |
14.0 months (from treatment) | 12.5% | Mean pre-VAS 5.1 Mean post-VAS 3.3 Median PRT 5.6 months |
| Ning [37] | 100 | N.S. | N.R. | 8.3 months | 23.2% | N.R. |
| Shi [38] | 71 | N.R. | N.R. | N.R. | N.R. | Pre-HIFU 70.42% painless Post-HIFU 92.96% painless |
| Sofuni [33] | 30 16 III |
N.S. | N.S. | N.R. | 10% | 66.7% (N.S.) ‡ |
| Sung [34] | 46 18 III |
N.S. | N.R. | N.S. | N.R. | Pre-VAS 4.9 Post-VAS 2.1 p < 0.001 (N.S.) |
| Wang [35] | 40 13 III |
N.S. | N.S. | 10 months | 0% | Total 35 (87.5%) (N.S.) Complete 9 (22.5%) Partial 26 (65%) Median PRT 10 weeks |
| Xiong [39] | 89 39 III |
N.S. | N.S. | 11.2 months | 11.2% | Total 54 (80.6%) (N.S.) Complete 21 (31.3%) Partial 33 (49.3%) † |
| Zhao H. [36] | 39 31 III |
N.S. | N.S. | N.S. | N.R. | Total 22 (78.6%) (N.S.) Complete 9 (32.1%) Partial 13 (46.4%) † |
| Zhao J. [40] | 38 | med 75 (62–80) | N.R. | 6.0 months vs. 10.3 months ~ | N.R. | N.R. |
pts = patients; N.S. = not specified (per stage); N.R. = not reported; III = stage 3 pancreatic cancer; VAS = visual analog scale; median PRT = median duration of pain relief time; RECIST 1.1 = new response evaluation criteria in solid tumours [28] * at 6 months after treatment; † NRS decrease by 2 or more; ‡ more than 30% improvement; ~ traditional HIFU 6 months vs. low power HIFU 10.3 months; p = 0.018.